FDA pulls emergency use authorization of hydroxychloroquine for COVID-19

By AHJ Staff June 17, 2020

The U.S. Food and Drug Administration recently rescinded its emergency use authorization for hydroxychloroquine to treat COVID-19. Based on new evidence, the agency said that the potential benefits of taking hydroxychloroquine and chloroquine to treat COVID-19 did not outweigh the risks (The New York Times).

AHJ Staff

American Healthcare Journal is healthcare’s No. 1 source for the latest insights, news and analysis. An authoritative, digital-first and editorially independent publication committed to providing decision makers with unparalleled thought leadership and objective, industry-focused information to help them run their businesses in the new era of healthcare.

Newsletter
Enter your email address to
subscribe to our newsletter.

Thank you for Signing Up
Please correct the marked field(s) below.
1,true,6,Subscriber Email,2
1,false,1,First Name,2
COVID-19 Resource Center ›
Featured Articles

October 30, 2020
What The Senior Caregiver Shortage Means For The Eldercare Industry

The main problem the eldercare industry faces today is one of supply and demand. Simply put, there are not enough caregivers to meet today’s demand. This problem will only get worse as baby boomers begin to enter their later senior years, in what is colloquially being called “The Gray Tsunami.”

Read More

October 29, 2020
Survey: Patient Volume At Most U.S. Physician Practices Expected To Return To Pre-COVID Levels By Jan. 1

A narrow majority of physician practices in the United States expect patient volume to return to pre-COVID levels by Jan. 1, 2021, according to a new Evolve Healthcare Marketing and Redwood Advisors survey. Fifty-one percent of outpatient physicians, practice administrators, hospital executives and other key healthcare decisionmakers made such a forecast when completing the inaugural survey late last summer. This total includes one-third of the survey’s participants whose volume had already returned to pre-pandemic levels before Labor Day.

Read More

October 23, 2020
Q&A: Senator Tom Daschle On The Future Of U.S Healthcare

Senator Tom Daschle of South Dakota is an important figure in U.S. legislative and regulatory policy, with 25 years of combined service in the U.S. House of Representatives and U.S. Senate. Daschle stands out as the only senator to serve twice as both the majority and minority leader. Daschle has participated in the development and debate of almost every major issue in the last three decades.

With his extensive experience and unique perspective, Tom Daschle discusses the future of U.S. healthcare with American Healthcare Journal staff writer, Caroline Miller.

Read More

FDA pulls emergency use authorization of hydroxychloroquine for COVID-19

Featured Articles

What The Senior Caregiver Shortage Means For The Eldercare Industry

Survey: Patient Volume At Most U.S. Physician Practices Expected To Return To Pre-COVID Levels By Jan. 1

Q&A: Senator Tom Daschle On The Future Of U.S Healthcare

Featured Articles

Survey: Patient Volume At Most U.S. Physician Practices Expected To Return To Pre-COVID Levels By Jan. 1

Q&A: Senator Tom Daschle On The Future Of U.S Healthcare

Support Community-Based Physicians In Our Fight Against COVID-19

How Healthcare Is Embracing Digital Technology And Contact Tracing To Fight Against COVID-19

FDA pulls emergency use authorization of hydroxychloroquine for COVID-19

Related Posts